Jove
Visualize
Contact Us

Related Experiment Videos

Colesevelam: a new bile acid sequestrant.

N N Wong1

  • 1Department of Pharmacy and Family Medicine, Montefiore Medical Center, Bronx, New York, USA. NWong@montefiore.org

Heart Disease (Hagerstown, Md.)
|April 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aggrenox: an aspirin and extended-release dipyridamole combination.

Heart disease (Hagerstown, Md.)·2002
Same author

Orlistat.

Heart disease (Hagerstown, Md.)·2001
Same author

Vergence adaptation in children and its clinical significance.

Binocular vision & strabismus quarterly·2001
Same author

Nearwork distances in children.

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2001
Same journal

Ximelagatran: a new oral anticoagulant.

Heart disease (Hagerstown, Md.)·2003
Same journal

Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).

Heart disease (Hagerstown, Md.)·2003
Same journal

A comparison of humanistic qualities among medical students, residents, and faculty physicians in internal medicine.

Heart disease (Hagerstown, Md.)·2003
Same journal

Effect of carotid angioplasty-stenting on short-term mortality and stroke.

Heart disease (Hagerstown, Md.)·2003
Same journal

Evidence for the extrapulmonary localization of inhaled nitric oxide.

Heart disease (Hagerstown, Md.)·2003
Same journal

Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart.

Heart disease (Hagerstown, Md.)·2003
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Colesevelam effectively lowers cholesterol, reducing risks for coronary heart disease. This bile acid sequestrant offers a promising alternative with potentially fewer gastrointestinal side effects compared to other treatments.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Coronary heart disease (CHD) is a leading cause of death in the US.
  • Hyperlipidemia, characterized by high total and low-density lipoprotein (LDL) cholesterol, is a major risk factor for CHD.
  • Effective lipid-lowering therapies are crucial for CHD prevention and management.

Purpose of the Study:

  • To evaluate the efficacy and safety of colesevelam, a novel bile acid sequestrant, in managing hyperlipidemia.
  • To assess colesevelam's impact on total cholesterol and LDL cholesterol levels.
  • To compare the effects of colesevelam, alone and in combination with statins, on lipid profiles.

Main Methods:

  • Review of short-term, placebo-controlled studies investigating colesevelam's effects on lipid levels.
  • Analysis of data from combination therapy studies involving colesevelam with atorvastatin, lovastatin, or simvastatin.

Related Experiment Videos

  • Assessment of colesevelam's formulation and potential for gastrointestinal tolerability.

    • Main Results:

    • Colesevelam demonstrated significant reductions in total cholesterol (6-10%) and LDL cholesterol (9-20%) in short-term studies.
    • Combination therapy with colesevelam and statins resulted in greater LDL cholesterol reduction than colesevelam monotherapy.
    • The unique hydrogel formulation of colesevelam may mitigate common gastrointestinal adverse effects associated with bile acid sequestrants.

    Conclusions:

    • Colesevelam is an effective agent for lowering total and LDL cholesterol levels.
    • Combination therapy with statins enhances the lipid-lowering effects of colesevelam.
    • Colesevelam presents a favorable tolerability profile, potentially offering an advantage over existing bile acid sequestrants.